Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Summary

This study evaluates the efficacy and safety of penpulimab plus lenalidomide, rituximab, gemcitabine and oxaliplatin (R2-GemOx) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). All patients will receive six cycles of penpulimab plus R2-GemOx. Afterwards, 1) patients who achieve complete response (CR)/unconfirmed (CRu)/partial response (PR) assessed by positron emission tomography/computedtomography (PET-CT) and are eligible for autologous stem cell transplantation (ASCT) will undergo ASCT. 2) Patients who achieve CR/CRu/PR assessed by PET-CT and are not eligible for ASCT will directly receive penpulimab and lenalidomide as maintenance treatment, penpulimab for a maximum of 6 months, lenalidomide monotherapy for 18 months. 3) Patients achieved stable disease (SD) or progression disease (PD) assessed by PET-CT will withdraw from this study and receive proper treatment based on investigator's decision.

Timeline

Start

2022-05-15

Primary completion

2024-01-15

Completion

2026-02-15

Publications

• Liang JH, Xing TY, Gu WY, Yin H, Zeng QS, Du KX, Sibusiso L, Wu JZ, Li Y, Wang F, Gao R, Li JY, Shen HR, Wang L, Xu W. Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial. BMC Med. 2026 Feb 9;24(1):156. doi: 10.1186/s12916-026-04679-1.

Drugs

Indications